Clinical Trials Browser

Withdrawn × veliparib × Clear all

Neoplasms

NCT03400306 2021-12-08

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Phase 1 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Phase 2 Withdrawn

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1 Withdrawn

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Clinical Trials

REPAIR

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor